UBS raised the firm’s price target on Travelers (TRV) to $298 from $290 and keeps a Neutral rating on the shares. Insurance brokers are well positioned for 2026, with organic revenue growth averaging 4.4% and EBITDA margins improving year over year despite property rate pressures, the analyst tells investors in a research note. With growth expectations reset and valuations reflecting a softer market, there is upside to consensus EPS and potential for multiple expansion, the firm says.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRV:
- Travelers price target raised to $315 from $291 at Citi
- Travelers price target raised to $295 from $287 at Argus
- Travelers price target raised to $320 from $317 at Keefe Bruyette
- Travelers price target lowered to $304 from $315 at Mizuho
- Travelers Companies Earnings Call Highlights Profitable Momentum